indol/obesity

FIELD OF THE INVENTION This invention relates to a series of 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine derivatives, pharmaceutical compositions containing them and intermediates used in their preparation. The compounds of the invention are ligands for the neuropeptide Y Y5 (NPY5) receptor, a

FIELD OF THE INVENTION This invention relates to a series of 3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine derivatives, pharmaceutical compositions containing them and intermediates used in their preparation. The compounds of the invention are ligands for the neuropeptide Y Y5 (NPY5) receptor, a

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT The research and development of the invention described below was not federally sponsored. FIELD OF THE INVENTION The present invention relates to a crystalline hydrochloride salt of

This invention relates to anti-obesity agents and their use in preventing or treating obesity in mammals, particularly humans. Hitherto the usual method employed to treat obesity in man has been to reduce the intake of food either by a low calorie diet or by the use of appetite suppressant

FIELD OF INVENTION The present invention relates to novel 3-(indol-3-yl)-pyridine derivatives, including pharmaceutically acceptable enantiomers, salts and solvates thereof. Compounds of the invention are inhibitors of TDO2 (tryptophan 2,3-dioxygenase) and are useful as therapeutic compounds,

BACKGROUND 1. Technical Field of Invention The present invention embodiments relate to novel 4-(indol-3-yl)-pyrazole derivatives, including pharmaceutically acceptable enantiomers, salts and solvates thereof. Compounds of certain embodiments of the invention are inhibitors of TDO2 (tryptophan

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the U.S. National Stage of International Application No. PCT/KR2007/004722, filed Sep. 27, 2007, which claims the benefit of Korean Patent Application KR10-2006-0094138, filed Sep. 27, 2006, both of which are hereby incorporated by

FIELD OF INVENTION The present invention relates to novel 3-(indol-3-yl)-pyridine derivatives, including pharmaceutically acceptable enantiomers, salts and solvates thereof. Compounds of the invention are inhibitors of TDO2 (tryptophan 2,3-dioxygenase) and are useful as therapeutic compounds,

CROSS-REFERENCES TO RELATED APPLICATION This patent application claims the benefit of priority under 35 U.S.C. .sctn.119 from Korean Patent Application No. 10-2008-0033284 filed Apr. 10, 2008, the contents of which are incorporated herein by reference. TECHNICAL FIELD The present disclosure relates

FIELD OF THE INVENTION The present invention is broadly directed to purine based compounds. More particularly, the present invention is directed to a novel purine analog having activity involving the serotonin neurotransmitter system in addition to other physiological activities and to associated